Obesity market news — August 31, 2026
Ascletis Pharma (ASC30): What changed: the first participant was dosed in the global Phase 3 programme of ASC30, a once-daily oral small molecule GLP-1 receptor agonist. Against what: until now the public record held Phase 1/2 data and an FDA clearance to begin Phase 3, with no evidence that any participant had been treated. When: August 30, 2026. Primary source: the company announcement and the two registrations, NCT07743463 (AURORA-1) and NCT07743450 (AURORA-2). The programme covers about 4,600 participants at sites in the United States, Europe and Canada, testing 20 mg, 40 mg and 60 mg maintenance doses over 72 weeks; AURORA-1 in participants without type 2 diabetes, AURORA-2 with it. Guided topline is the third quarter of 2028, an FDA submission by the end of 2028 and an EMA submission in early 2029. One framing point matters: the company itself describes ASC30 as a candidate to become the second oral small molecule GLP-1 in the United States and Europe, which places it behind orforglipron rather than against it. This is a 2029 question, not a 2026 one.
Structure Therapeutics (GPCR), Viking Therapeutics (VKTX), Zealand Pharma (ZEAL): What did not change, which in a change log is the entry that matters. Three guided windows in the followed field close within about a month, and as of August 31 none had been filled. Structure Therapeutics has said it is on track to start the Phase 3 programme of aleniglipron, an oral small molecule GLP-1, in the third quarter of 2026, at a 2.5 mg starting dose, following its end of Phase 2 meeting with the FDA. Viking Therapeutics has guided topline data from VANQUISH-2, the Phase 3 trial in participants with type 2 diabetes, to the third quarter of 2026. Zealand Pharma and Roche, in their half-year report of August 13, guided the start of registrational Phase 3 trials of petrelintide monotherapy to the second half of 2026. The third quarter ends on September 30. We are not forecasting slippage; we are recording that three dated commitments are open with about four weeks left, and that the Ascletis start is so far the only one of the group that has been met.
Viking Therapeutics (VKTX): A distinction worth keeping straight, because the two trials are routinely conflated in coverage. VANQUISH-2 is the smaller study, about 1,000 participants with type 2 diabetes; enrolment completed in the first quarter of 2026 and topline is guided to the third quarter of 2026. VANQUISH-1 is the larger one, about 4,650 participants without type 2 diabetes; enrolment completed in the fourth quarter of 2025 and topline is guided to the first half of 2027. Both test VK2735 by weekly subcutaneous injection over 78 weeks. A headline that says Viking reports Phase 3 data in 2026 is describing the smaller diabetes trial, not the main obesity readout. Nothing changed here this week. The entry exists because the confusion recurs, and because the two dates sit eighteen months apart.
Eli Lilly (LLY), Novo Nordisk (NVO): Neither market leader produced a dated change in this window, and no new regulatory decision touched the followed companies between August 25 and August 31. That is worth stating plainly, because the Ascletis start will be read in some coverage as a competitive event. Both leaders already have an oral product on the market: orforglipron, sold as Foundayo, and oral semaglutide, sold as the Wegovy pill. The question the Ascletis start actually raises is not who supplies the market in 2026 but who arrives third, at the end of the decade, and on what label. Disclosure: the author holds shares in Eli Lilly and Novo Nordisk. The full statement is on the About page.